Chagas Disease Diagnostic Composition Using Three Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Chagas disease face challenges in reproducibility, sensitivity, and specificity due to the complex antigen composition of Trypanosoma cruzi, leading to high production costs and the need for multiple assays to achieve reliable results, with no economically affordable gold standard available.
Innovation Solution
A diagnostic composition and method using a mixture of three Trypanosoma cruzi specific polypeptides, 1F8, JL7, and at least one of Cruzipain, KMP-11, or PAR2, which are recombinantly produced and used in an in vitro diagnostic assay to detect antibodies, overcoming the limitations of prior art by achieving superior reproducibility, sensitivity, and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native antigen lysates are used for diagnostic assays, then the assay can detect antibodies against T. cruzi, but the specificity is reduced due to cross-reactivities with other parasites like Leishmania
Solution Approach 1:
The patent extracts only the essential immunogenic components (three specific polypeptides: 1F8, JL7, and Cruzipain) from the complex native antigen lysate. This extraction eliminates non-specific components that cause cross-reactivity with other parasites while retaining the ability to detect anti-T. cruzi antibodies, thereby resolving the contradiction between maintaining detection capability and reducing cross-reactivity.
Solution Approach 2:
The patent applies local quality by selecting polypeptides with specific properties - choosing 1F8, JL7, and Cruzipain based on their demonstrated ability to elicit stage-specific antibodies without cross-reacting with Leishmania or other parasites. Each polypeptide is selected for its unique immunological characteristics, creating a tailored antigen composition that optimizes specificity while maintaining sensitivity.
2Reliability
If complex antigen compositions are used to improve sensitivity, then detection capability increases, but production costs and assay complexity increase
Solution Approach 1:
The patent extracts only the three most critical polypeptides (1F8, JL7, Cruzipain) from the complex antigen composition, eliminating redundant components. This extraction maintains high sensitivity by preserving the essential immunogenic elements while significantly reducing assay complexity and production costs associated with manufacturing and handling multiple antigens.
Solution Approach 2:
Instead of starting with a complex native lysate and trying to simplify it, the patent inverts the approach by directly producing only the three essential recombinant polypeptides. This inversion from reduction to selective production simplifies manufacturing processes, reduces costs, and eliminates the need to manage complex antigen mixtures while maintaining diagnostic sensitivity.
3Reliability
If multiple assays are performed to achieve reliable results, then diagnostic accuracy improves, but time consumption and costs increase
Solution Approach 1:
The patent merges the diagnostic capability of multiple separate assays into a single integrated assay using the three-polypeptide composition. The combination of 1F8, JL7, and Cruzipain antigens provides comprehensive coverage of different infection stages, allowing a single test to deliver the diagnostic accuracy that previously required multiple sequential assays, thereby eliminating time loss and reducing operational costs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these specific polypeptides provides a reliable and cost-effective diagnostic solution with high specificity (around 99.8%) and sensitivity, reducing the need for multiple assays and lowering production costs, while maintaining or exceeding the performance of commercial assays.
Implementation Method 1
a composition of Trypanosoma cruzi polypeptides is used as a capture reagent and/or as a binding partner for said Trypanosoma cruzi antibodies
Data Source
Figure 1a
Figure 1b
Figure 2
AI summary
The present invention concerns a composition of polypeptides suitable for detecting antibodies against Trypanosoma cruzi (T. cruzi) in an isolated biological sample consisting of three polypeptides 1F8, JL7 and Cruzipain. A method of producing a soluble and immunoreactive composition of polypeptides suitable for detecting antibodies against T. cruzi using said composition of polypeptides is also part of the invention. Moreover, the invention concerns a method for detecting antibodies specific for T. cruzi in an isolated sample wherein a composition of said T. cruzi polypeptides is used as well as a reagent kit comprising said composition of T. cruzi polypeptides.